SelfWrap
Improvement of arteriovenous (AV) access site maturation and patency for hemodialysis
Pivotal TrialActive
Key Facts
Indication
Improvement of arteriovenous (AV) access site maturation and patency for hemodialysis
Phase
Pivotal Trial
Status
Active
Company
About VenoStent
VenoStent is a private, clinical-stage medical device company targeting a critical unmet need in vascular surgery: the failure of dialysis access sites. Its core technology is SelfWrap, a bioabsorbable, 3D-printed perivascular wrap intended to improve the maturation and patency of AV fistulas and grafts. The company has secured FDA Breakthrough Device designation, completed a $16M Series A financing, and initiated a 200-subject US clinical trial, positioning it to address a multi-billion-dollar cost burden for Medicare.
View full company profile